As we reported here, Momenta is appealing a PTAB decision upholding the patentability of BMS’s U.S. Patent No. 8,476,239 (“the ’239 patent”), which relate to BMS’s Orencia® (abatacept) product.
Bristol-Myers Squibb has become the latest drugmaker in the US to file a legal challenge to a block on a drug rebate model opposed by a Health and Human Services (HHS) department. Specifically, BMS is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback